- Home
- STG vs ABVC Comparison
STG vs ABVC Comparison
Compare STG & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STG | ABVC |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.3M | 50.5M |
| IPO Year | 2017 | 2009 |
Fundamental Metrics
Financial Performance| Metric | STG | ABVC |
|---|---|---|
| Price | $4.40 | $1.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.5K | ★ 49.9K |
| Earning Date | 01-01-0001 | 06-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $509,589.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.28 | $0.61 |
| 52 Week High | $15.00 | $4.02 |
Technical Indicators
Market Signals| Indicator | STG | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 32.89 |
| Support Level | $4.28 | $1.15 |
| Resistance Level | $4.87 | $1.67 |
| Average True Range (ATR) | 0.13 | 0.13 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 14.56 | 18.18 |
Price Performance
Historical ComparisonAbout STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.